Literature DB >> 11123038

Circulating endothelial cells and vascular injury in systemic lupus erythematosus.

R M Clancy1.   

Abstract

In flares of systemic lupus erythematosus (SLE), endothelial cells activated by immune stimuli are potential participants in the inflammatory processes, which contribute to injury. Elevated levels of circulating endothelial cells (CEC) may be a proxy for vascular injury, as demonstrated in patients with sickle cell anemia during acute crises. In active SLE, CEC levels in peripheral blood are elevated (vs healthy controls and correlate with plasma C3a). CEC may reflect widespread unrecognized, ongoing injury despite the absence of clinical stigmata of vasculitis in patients with SLE.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11123038     DOI: 10.1007/s11926-996-0067-6

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  25 in total

1.  Cytofluorometric detection of human endothelial cells in whole blood using S-Endo 1 monoclonal antibody.

Authors:  F George; P Poncelet; J C Laurent; O Massot; D Arnoux; N Lequeux; P Ambrosi; C Chicheportiche; J Sampol
Journal:  J Immunol Methods       Date:  1991-05-17       Impact factor: 2.303

2.  Outside-in signaling in the chondrocyte. Nitric oxide disrupts fibronectin-induced assembly of a subplasmalemmal actin/rho A/focal adhesion kinase signaling complex.

Authors:  R M Clancy; J Rediske; X Tang; N Nijher; S Frenkel; M Philips; S B Abramson
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

3.  Tissue factor expression by endothelial cells in sickle cell anemia.

Authors:  A Solovey; L Gui; N S Key; R P Hebbel
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

4.  Circulating activated endothelial cells in sickle cell anemia.

Authors:  A Solovey; Y Lin; P Browne; S Choong; E Wayner; R P Hebbel
Journal:  N Engl J Med       Date:  1997-11-27       Impact factor: 91.245

5.  Damage to the vascular endothelium of diabetic patients can be assessed by analysing blood samples for the number of circulating endothelial cells with mitochondrial DNA deletions.

Authors:  D N Egawhary; B E Swoboda; J Chen; F P Vince
Journal:  Biochem Soc Trans       Date:  1995-08       Impact factor: 5.407

6.  A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death.

Authors:  S Rosner; E M Ginzler; H S Diamond; M Weiner; M Schlesinger; J F Fries; C Wasner; T A Medsger; G Ziegler; J H Klippel; N M Hadler; D A Albert; E V Hess; G Spencer-Green; A Grayzel; D Worth; B H Hahn; E V Barnett
Journal:  Arthritis Rheum       Date:  1982-06

7.  Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection.

Authors:  A Grefte; M van der Giessen; W van Son; T H The
Journal:  J Infect Dis       Date:  1993-02       Impact factor: 5.226

8.  Interactions of leukocyte integrins with intercellular adhesion molecule 1 in the production of inflammatory vascular injury in vivo. The Shwartzman reaction revisited.

Authors:  L W Argenbright; R W Barton
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

9.  Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited.

Authors:  H M Belmont; J Buyon; R Giorno; S Abramson
Journal:  Arthritis Rheum       Date:  1994-03

10.  Complement-mediated regulation of tissue factor activity in endothelium.

Authors:  S Saadi; R A Holzknecht; C P Patte; D M Stern; J L Platt
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

View more
  11 in total

Review 1.  Understanding mechanisms of hypertension in systemic lupus erythematosus.

Authors:  Erin B Taylor; Michael J Ryan
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-03-15

2.  Persistent hypertension in lupus nephritis and the associated risk factors.

Authors:  Syahrul Syazliana Shaharir; Ruslinda Mustafar; Rozita Mohd; Mohd Shahrir Mohd Said; Halim A Gafor
Journal:  Clin Rheumatol       Date:  2014-11-06       Impact factor: 2.980

3.  Circulating endothelial cells in Kawasaki disease.

Authors:  K Nakatani; S Takeshita; H Tsujimoto; Y Kawamura; T Tokutomi; I Sekine
Journal:  Clin Exp Immunol       Date:  2003-03       Impact factor: 4.330

Review 4.  Update on Biomarkers of Vasculopathy in Juvenile and Adult Myositis.

Authors:  Kirsty McLellan; Charalampia Papadopoulou
Journal:  Curr Rheumatol Rep       Date:  2022-06-10       Impact factor: 4.686

5.  Clinical Features according to the Frequency of Acute Exacerbation in COPD.

Authors:  Seung Jun Lee; Seung Hun Lee; Yu Eun Kim; Yu Ji Cho; Yi Yeong Jeong; Ho Cheol Kim; Jin Hyun Kim; Jin Jong You; Chul-Ho Yoon; Jong Deog Lee; Young Sil Hwang
Journal:  Tuberc Respir Dis (Seoul)       Date:  2012-04-30

Review 6.  The pathophysiology of hypertension in systemic lupus erythematosus.

Authors:  Michael J Ryan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-01-21       Impact factor: 3.619

Review 7.  The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus.

Authors:  J Michelle Kahlenberg; Mariana J Kaplan
Journal:  Arthritis Res Ther       Date:  2011-02-28       Impact factor: 5.156

Review 8.  Imbalance between endothelial damage and repair: a gateway to cardiovascular disease in systemic lupus erythematosus.

Authors:  Anselm Mak; Nien Yee Kow
Journal:  Biomed Res Int       Date:  2014-03-26       Impact factor: 3.411

9.  Neutralizing interferon-α blocks inflammation-mediated vascular injury via PI3K and AMPK in systemic lupus erythematosus.

Authors:  Xuewei Ding; Wei Xiang; Ren Yi; Xiaoyan Huang; Qiuyu Lin; Xiaojie He
Journal:  Immunology       Date:  2021-06-20       Impact factor: 7.215

Review 10.  Circulating endothelial cells, microparticles and progenitors: key players towards the definition of vascular competence.

Authors:  F Sabatier; L Camoin-Jau; F Anfosso; J Sampol; F Dignat-George
Journal:  J Cell Mol Med       Date:  2009-03       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.